Short answer

A useful peptide COA should connect one identifiable batch to reproducible analytical evidence. Check the sample or batch identifier first, then separate identity evidence from purity and content measurements. Confirm the laboratory, test date, analytical methods, numerical results, and any public verification key. A purity percentage alone does not establish molecular identity or the amount of peptide in a vial.

Key facts

  • Identity, purity and content answer different questions and should not be treated as interchangeable.
  • The batch or sample identifier on the report should match the material being supplied.
  • A public verification key is useful only when the laboratory record matches the unedited report.
  • Method details such as detector wavelength, column and gradient show whether a result fits its stated purpose.
  • A mass result is only meaningful when the report states the charge state, the ion type and the expected value it was compared with.
  • A COA is one part of supplier qualification, not a substitute for traceability and receiving controls.

Start with report identity and traceability

Before reading any number, establish what the report describes. A certificate that cannot be tied to a specific batch is a statement about a product type, not evidence about the vial on the bench. Preserve the original file, because changing the client, manufacturer, QR code, signature, result or verification text breaks the link to the laboratory record.

  • The issuing laboratory and its contact details
  • A task, report or sample number, and any verification key or QR destination
  • The client and manufacturer names as they appear on the laboratory record
  • The product name, the batch identifier and the testing and release dates
  • The signature or approval of a named person

If the supplied vial carries a different batch code, the report may still describe the same compound, but it is not batch-specific evidence for that vial. The guide to batch-specific verification explains how to document this link.

Separate identity, purity and content

Three questions are often collapsed into one number. Identity asks whether the main substance is the expected molecule. Purity asks what share of the detected signal belongs to the main peak. Content asks how much target material is in the vial. A report can show high chromatographic purity while the measured content differs from the label, so each result should be reviewed on its own.

QuestionTypical testWhat it cannot tell you
Is it the right molecule?Mass spectrometry, sometimes MS/MS or amino acid analysisHow much of the powder is that molecule
How pure is the main peak?RP-HPLC with UV detectionIdentity, and anything that does not absorb at the chosen wavelength
How much peptide is in the vial?Amino acid analysis, quantitative NMR or a validated content assayWhether the peptide is the right sequence
How much water and counter-ion?Karl Fischer titration; ion chromatography or 19F NMR for TFAPeptide purity

Read the HPLC result in context

Do not stop at the printed purity percentage. Review the chromatogram itself, the detector and its wavelength, the column, the mobile phases, the gradient, the run time, the retention time of the main peak and the way peaks were integrated. Peptides are normally detected at 214 or 220 nm, where the peptide bond absorbs, and area normalization compares integrated responses at that wavelength only.

Impurities that do not absorb there are invisible, and impurities that co-elute with the main peak are counted as part of it.

  • A baseline blank run shows which peaks belong to the system rather than the sample.
  • A visible shoulder on the main peak suggests a closely related impurity that the integration may have merged.
  • The integration threshold decides which small peaks are counted at all.
  • The same sample can give different percentages with different gradients.

The guide to reading an HPLC chromatogram goes through these points with examples.

Review the mass-spectrometry evidence

Check whether the report gives the expected formula or mass, the observed ions, their charge states and a calculated or deconvoluted mass. Peptides usually carry several charges, so a raw mass-to-charge value is not the intact mass. For a 1,000 Da peptide, the singly charged ion appears near m/z 1001 and the doubly charged ion near m/z 501.

The observed result should be explained by the expected molecule, the ionization mode, the salt form and any adducts. Agreement within a few tenths of a dalton is typical for a low-resolution instrument, and within a few parts per million for a high-resolution one.

Compare the numbers with the reference values on the compound page for the product. If the report compares an observed mass with an expected value, the expected value should be stated on the report, along with whether it is monoisotopic or average.

Look for content, water and counter-ion data

A lyophilized peptide is a salt. The powder holds counter-ions such as trifluoroacetate or acetate and a few percent of water, so the peptide is only part of the weighed mass. A report that gives net peptide content, water content and counter-ion information lets a laboratory work out how much peptide a vial contains. A report that gives only a purity percentage leaves that question open.

Recognise common warning signs

Some features do not prove a problem but justify a question to the supplier before the material is accepted.

  • Only a purity percentage, with no chromatogram
  • No batch identifier, or an identifier that differs from the vial
  • A chromatogram cropped so that the baseline and early or late peaks are not visible
  • A mass listed without a charge state, an ion type or an expected value
  • Identical-looking reports for different compounds, with only the name changed
  • A verification key or QR code that opens a page that does not match the printed report

Use a repeatable acceptance checklist

A receiving laboratory can document five decisions: the report is authentic, the material and the report are traceably linked, the methods are appropriate, the results meet internal specifications, and any discrepancy has been resolved before release. Keep the report, the verification evidence, the purchase record, photographs of the received batch and the internal decision together.

The compound identity file template gives a layout for this record.

Frequently asked questions

Does 99% HPLC purity mean the vial contains 99% of the labeled amount?

No. HPLC area purity and measured vial content are different measurements. A separate quantitative assay or content test is needed to evaluate the amount present.

Can a supplier rename the client on a third-party COA after rebranding?

The original laboratory report should remain unedited. A supplier can add a separate rebranding note, but an amended client or manufacturer field should come from the issuing laboratory.

Is one analytical technique enough for peptide verification?

It depends on the claim and method, but orthogonal evidence is stronger. Chromatography can support purity assessment while mass spectrometry can support molecular identity.

What mass difference between observed and expected is acceptable?

That depends on the instrument and the laboratory's own specification. As a rule of thumb, a low-resolution instrument agrees within a few tenths of a dalton and a high-resolution one within a few parts per million. State the tolerance in advance and apply it to the deconvoluted or monoisotopic mass, not to a single raw m/z value.

Should a COA include the chromatogram?

Yes. The percentage is a summary of the chromatogram, and the trace shows whether the main peak is symmetric, whether there are shoulders and how the baseline looks. A report without the trace cannot be reviewed.

What should I do if the batch code on the report does not match the vial?

Quarantine the material and ask the supplier in writing for the report that matches the vial. Do not release the batch on the basis of a report for another lot.

Primary references

  1. ICH Q2(R2): Validation of Analytical Procedures
  2. FDA: Analytical Procedures and Methods Validation for Drugs and Biologics
  3. USP General Chapter 621: Chromatography

Related guides

Compound references · Research areas · Glossary · Methodology · All resources